For many years the backbone of treatment for many gynaecological cancers has involved the use of platinum and taxane chemotherapy in both the adjuvant and metastatic setting, with survival rates for patients with advanced disease remaining sub-optimal.
However, recent trials have demonstrated survival benefits with the addition of more targeted therapies including anti-angiogenic agents and parp inhibitors. An increased role for the use of systemic therapies in the adjuvant treatment of endometrial and cervical cancer is also being investigated in collaborative international randomized trials. On overview of practice changing trials of new approaches to systemic therapies in gynaecological cancer will be presented. Many of these trials have involved Australian patients and international collaboration via the Australia New Zealand Gynaecological Oncology Group (ANZGOG) and the Gynecologic Cancer InterGroup (GCIG). In addition, early phase trials of innovative combinations of immunotherapies and other targeted agents being performed in Australia will be described.